Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe

Published:2018-12-07 Issue:8 Volume:1 Page:e185554
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Khunti Kamlesh¹,Danese Mark D.²,Kutikova Lucie³,Catterick David⁴,Sorio-Vilela Francisco³,Gleeson Michelle²,Kondapally Seshasai Sreenivasa Rao⁵,Brownrigg Jack⁶⁷,Ray Kausik K.⁷⁸

Affiliation:

1. Diabetes Research Centre, University of Leicester, Leicester, United Kingdom

2. Outcomes Research, Outcomes Insights, Inc, Westlake Village, California

3. Health Economics, Amgen Europe GmbH, Zug, Switzerland

4. Amgen Limited, Uxbridge, United Kingdom

5. St George’s University of London, London, United Kingdom

6. St George’s Vascular Institute, London, United Kingdom

7. currently with Rare Diseases, Pfizer, London, United Kingdom

8. Imperial Centre for Cardiovascular Disease Prevention, School of Public Health, Imperial College London, London, United Kingdom

Publisher

American Medical Association (AMA)

Subject

General Medicine

Reference29 articles.

1. 2016 ESC/EAS guidelines for the management of dyslipidaemias.;Catapano;Eur Heart J,2016

2. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3).;JBS3 Board;Heart,2014

3. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.;Stone;Circulation,2014

4. 2016 European guidelines on cardiovascular disease prevention in clinical practice.;Piepoli;Eur Heart J,2016

5. General practitioners’ decision making about primary prevention of cardiovascular disease in older adults: a qualitative study.;Jansen;PLoS One,2017

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lifelong prevention of atherosclerotic cardiovascular disease (ASCVD) through LDL-C control - Means and cost/benefit of sustained very low lifetime LDL-C targets;American Journal of Preventive Cardiology;2024-09

2. Letter by Highton and Khunti Regarding Article, “Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial”;Circulation: Cardiovascular Quality and Outcomes;2024-08

3. Adherence and persistence to novel glucose-lowering medications in persons with type 2 diabetes mellitus undergoing routine care;Diabetes Research and Clinical Practice;2024-07

4. Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease;Reviews in Cardiovascular Medicine;2024-05-23

5. New targets and mechanisms of action for lipid-lowering and anti-inflammatory therapies in atherosclerosis: where does the field stand?;Expert Opinion on Therapeutic Targets;2024-05-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3